H-1B sponsorship profile: Bioverativ Therapeutics, Inc. Across U.S. Department of Labor LCA disclosures, Bioverativ Therapeutics, Inc filed 10 Labor Condition Applications covering 10 H-1B worker positions between fiscal year 2023 and fiscal year 2025. The employer’s DOL certification rate sits at 90% (9 certified of 10 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Bioverativ Therapeutics, Inc’s H-1B petitions range from $93,150 at the low end to $143,686 at the high end, with a petition-weighted average of $111,898. That range reflects the mix of occupations the company sponsors, led by Senior Associate Scientist, Rare Blood Disorders (3 petitions at $93,150 avg), followed by Scientist, Complement Research and Scientist. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Bioverativ Therapeutics, Inc is headquartered in Waltham, MA under NAICS code 32541, and places H-1B workers across 1 state, most heavily in MA. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Bioverativ Therapeutics, Inc ranks. By H-1B petition volume, Bioverativ Therapeutics, Inc is #16,610 of 119,880 employers nationally and #720 of 5,193 employers headquartered in MA. Both ranks are computed live from the same underlying petition counts, not a separate estimate.